Author:
White Andrew D.,Tran Andy C.,Sibley Laura,Sarfas Charlotte,Morrison Alexandra L.,Lawrence Steve,Dennis Mike,Clark Simon,Zadi Sirine,Lanni Faye,Rayner Emma,Copland Alastair,Hart Peter,Diogo Gil Reynolds,Paul Matthew J.,Kim Miyoung,Gleeson Fergus,Salguero Francisco J.,Singh Mahavir,Stehr Matthias,Cutting Simon M.,Basile Juan I.,Rottenberg Martin E.,Williams Ann,Sharpe Sally A.,Reljic Rajko
Abstract
Tuberculosis remains a major health threat globally and a more effective vaccine than the current Bacillus Calmette Guerin (BCG) is required, either to replace or boost it. The Spore-FP1 mucosal vaccine candidate is based on the fusion protein of Ag85B-Acr-HBHA/heparin-binding domain, adsorbed on the surface of inactivated Bacillus subtilis spores. The candidate conferred significant protection against Mycobacterium. tuberculosis challenge in naïve guinea pigs and markedly improved protection in the lungs and spleens of animals primed with BCG. We then immunized rhesus macaques with BCG intradermally, and subsequently boosted with one intradermal and one aerosol dose of Spore-FP1, prior to challenge with low dose aerosolized M. tuberculosis Erdman strain. Following vaccination, animals did not show any adverse reactions and displayed higher antigen specific cellular and antibody immune responses compared to BCG alone but this did not translate into significant improvement in disease pathology or bacterial burden in the organs.
Subject
Immunology,Immunology and Allergy